Terms: = Germ cell tumor AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Prognosis
36 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS.
Yamada CAF; Malheiros SMF; Do Amaral LLF; Lancellotti CLP
Exp Oncol; 2023 Dec; 45(3):297-311. PubMed ID: 38186025
[TBL] [Abstract] [Full Text] [Related]
3. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
Li K; Liu Y; Han J; Gui J; Zhang X
Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
[TBL] [Abstract] [Full Text] [Related]
4. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch repair proteins PMS2 and mlh1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract] [Full Text] [Related]
6. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract] [Full Text] [Related]
7. [A Case of Medullary Carcinoma of the Colon with Poor prognosis].
Tamai K; Okamura S; Kitahara T; Minoji T; Takabatake H; Watanabe N; Yamamura N; Fukuchi N; Ebisui C; Yokouchi H; Kinuta M; Ohishi K
Gan To Kagaku Ryoho; 2020 Apr; 47(4):637-639. PubMed ID: 32389968
[TBL] [Abstract] [Full Text] [Related]
8. Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with mlh1/PMS2 Immunodeficiency and Minimal Microsatellite Shift.
Vanoli A; Perfetti V; Furlan D; Neri G; Viglio A; Sessa F; Martino M; Di Sabatino A; Solcia E; La Rosa S
Endocr Pathol; 2020 Dec; 31(4):411-417. PubMed ID: 32388775
[TBL] [Abstract] [Full Text] [Related]
9. Homogeneous MMR Deficiency Throughout the Entire tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract] [Full Text] [Related]
10. Microsatellite Instability in Glioblastoma: Is It Really Relevant in tumor prognosis?
Tepeoglu M; Borcek P; Ozen O; Altinors N
Turk Neurosurg; 2019; 29(5):778-784. PubMed ID: 31529454
[TBL] [Abstract] [Full Text] [Related]
11. Colorectal large-cell neuroendocrine carcinoma with lymphoid stroma: further evidence confirming a unique subtype associated with mlh1/PMS2 loss, BRAF mutation, Epstein-Barr virus negativity, and the possibility of a better prognosis.
Chetty R; Capo-Chichi JM; Serra S
Histopathology; 2019 Aug; 75(2):247-253. PubMed ID: 30990915
[TBL] [Abstract] [Full Text] [Related]
12. Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.
Tlemsani C; Leroy K; Gimenez-Roqueplo AP; Mansuet-Lupo A; Pasmant E; Larousserie F; Boudou-Rouquette P; Vidaud M; Cadranel J; Blons H; Goldwasser F; Laurent-Puig P
J Med Genet; 2020 Feb; 57(2):104-108. PubMed ID: 30352869
[TBL] [Abstract] [Full Text] [Related]
13. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract] [Full Text] [Related]
14. Glioblastoma in England: 2007-2011.
Brodbelt A; Greenberg D; Winters T; Williams M; Vernon S; Collins VP;
Eur J Cancer; 2015 Mar; 51(4):533-542. PubMed ID: 25661102
[TBL] [Abstract] [Full Text] [Related]
15. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.
Sahnane N; Furlan D; Monti M; Romualdi C; Vanoli A; Vicari E; Solcia E; Capella C; Sessa F; La Rosa S
Endocr Relat Cancer; 2015 Feb; 22(1):35-45. PubMed ID: 25465415
[TBL] [Abstract] [Full Text] [Related]
16. Medullary carcinoma of the colon: can the undifferentiated be differentiated?
Fiehn AM; Grauslund M; Glenthøj A; Melchior LC; Vainer B; Willemoe GL
Virchows Arch; 2015 Jan; 466(1):13-20. PubMed ID: 25339302
[TBL] [Abstract] [Full Text] [Related]
17. [Pathologic analysis of upper tract urothelial carcinomas: state of the art review for the yearly scientific report of the French National Association of Urology].
Varinot J; Colin P; Rouprêt M; Leroy X; Comperat E
Prog Urol; 2014 Nov; 24(15):954-65. PubMed ID: 25199727
[TBL] [Abstract] [Full Text] [Related]
18. High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma.
Alvino E; Passarelli F; Cannavò E; Fortes C; Mastroeni S; Caporali S; Jiricny J; Cappellini GC; Scoppola A; Marchetti P; Modesti A; D'Atri S
Am J Clin Pathol; 2014 Jul; 142(1):121-32. PubMed ID: 24926095
[TBL] [Abstract] [Full Text] [Related]
19. Integrated analysis of mismatch repair system in malignant astrocytomas.
Rodríguez-Hernández I; Garcia JL; Santos-Briz A; Hernández-Laín A; González-Valero JM; Gómez-Moreta JA; Toldos-González O; Cruz JJ; Martin-Vallejo J; González-Sarmiento R
PLoS One; 2013; 8(9):e76401. PubMed ID: 24073290
[TBL] [Abstract] [Full Text] [Related]
20. Promoter methylation of AREG, HOXA11, hmlh1, NDRG2, NPTX2 and Tes genes in glioblastoma.
Skiriutė D; Vaitkienė P; Ašmonienė V; Steponaitis G; Deltuva VP; Tamašauskas A
J Neurooncol; 2013 Jul; 113(3):441-9. PubMed ID: 23624749
[TBL] [Abstract] [Full Text] [Related]
[Next]
